ArticleRespiratory research2026
Immune-related adverse event profiles and survival outcomes in non-small cell lung cancer: a cluster analysis from a long-term real-world study.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmune-related adverse events (irAEs) are heterogeneous in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize post-treatment irAE phenotypes and explore their temporal and survival associations.
methodsWe retrospectively analyzed 202 patients with pathologically confirmed NSCLC who received at least two cycles of ICI therapy. Mixed irAE features were integrated using factor analysis of mixed data (FAMD) and clustered by K-means. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier and landmark analyses. Time-dependent Cox models were used to account for delayed irAE-cluster formation, and Fine-Gray models evaluated baseline predictors of irAE occurrence with death treated as a competing event.
resultsFAMD-based clustering identified five descriptive post-treatment irAE phenotypes: multiorgan non-hepatic/gastrointestinal, hepatic/gastrointestinal-enriched multiorgan, irAE-negative, other/atypical, and thyroid-dominant endocrine phenotypes. Conventional Kaplan-Meier analysis showed longer observed OS in patients with any irAE than in those without irAEs (median OS, 30.5 vs. 20.0 months; hazard ratio, 0.68; 95% CI, 0.47-0.99). However, survival patterns differed across irAE phenotypes, and PFS did not differ significantly by irAE occurrence or across clusters. In time-dependent Cox analyses, the hepatic/gastrointestinal-enriched multiorgan phenotype was consistently associated with poorer subsequent OS, highlighting heterogeneity beyond overall irAE occurrence. Fine-Gray analyses identified radiotherapy and older age as baseline factors associated with a higher cumulative incidence of irAEs. Cluster stability analyses showed acceptable overall reproducibility, although smaller clusters required cautious interpretation.
conclusionsData-driven irAE phenotypes captured heterogeneity in the timing and organ distribution of immune toxicity among ICI-treated NSCLC patients. Integrating irAE organ distribution and timing may provide exploratory prognostic information beyond overall irAE occurrence, but these findings should be interpreted cautiously because irAE clusters were post-treatment phenotypes and may be influenced by treatment exposure and survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.